Trial | NCT01493440  Report issue

Official Title

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    Atosiban ...

  • Study Participants

    71
Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).
Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
Study Started
Mar 31
2011
Primary Completion
Aug 31
2011
Study Completion
Sep 30
2011
Last Update
Dec 20
2011
Estimate

Drug atosiban

Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

  • Other names: Tractocile

Atosiban Other

Criteria 

Inclusion Criteria:

had repeated implantation failure
have at least 1 good quality embryo for transfer

Exclusion Criteria:

uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
No Results Posted